Hydroxychloroquine Market Size Worth Around US$ 6 Bn by 2027

LOS ANGELES, May 13, 2020 /PRNewswire/ -- The global hydroxychloroquine market size is expected to be worth around US$ 6 Bn by 2027 with CAGR of around 32%.


The commercial market for hydroxychloroquin is witnessing growth owing to the rising demand for the medication as a possible cure of the COVID-19 pandemic disease. However, the growing incidence of autoimmune disorders, including rheumatoid arthritis and lupus erythematosus, is fuelling demand worldwide. However, increased malaria cases have further improved drug development in developing and underdeveloped nations, such as India and the African economies. For example, 19 African countries and India bore approximately 85 percent of the total burden of malaria, as per the World Health Organization (WHO). The probable side effects of hydroxychloroquine can hinder market development during the prediction period.

Get Free Report Sample Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1858

Increasing Coronavirus Disease (COVID-19) Cases Impacts on the Market

The recently discovered Coronavius disease, COVID-19, erupted quickly in over 200 nations across the world in late November 2020. Coronavirus is primarily spread from infected individuals by reparatory goutlets. No different COVID-19 therapies or vaccines are currently available. However, a number of clinical trials and R&D studies are being performed to create a infectious prevention vaccine. While, in live experiments as well as experimental research, hydroxychloroquine has proved to be a game-changer that is effective in treating COVID-19. As a result, the worldwide market for hydroxychloroquine is increasing exponentially. India is a leading producer of this antimalarial drug, and many Indian companies have expanded their hydroxychloroquine production to satisfy local and export demand. Although the efficacy of hydroxychloroquine for COVID-19 therapy is not tested in a wide scale clinical study, the medication is still missing in pharmacies. India reportedly produces 40 tons of hydroxychloroquine per month or 20 crore tablets of 200 mg each. For developed countries such as the United States and Western nations, the medication is not made, as malaria is practically non-existent. Therefore, hydroxychloroquine from India is being requested by several countries by the global COVID-19 pandemic.

Asia Pacific Govern the Global Market

Asia Pacific accounted for the world's largest market share, while North America is estimated to rise at substantial CAGR during the forecast period. In Asia Pacific, India was the largest hydroxychloroquine manufacturer and accounted for over 70% of the overall global drug capacities. High prevalence of malaria in India is the principal factor promoting hydroxychloroquine development in the country. In addition, the current scenario is boosting the demand for medicines from the world and enhancing their development in India because of the positive effects of hydroxychloroquine in the manufacturing of COVID-19. Moreover, China is the largest source of active pharmaceutical ingredients (APIs) used as the primary raw material in the manufacture of hydroxychloroquine, making a substantial contribution to global advancement in the hydroxychloroquine industry.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/hydroxychloroquine-market

About the Market

Hydroxychloroquine is a antimalarial treatment. In addition to malaria, lupus erythematosus, rheumatoid arthritis, Q fever, and the newly diagnosed COVID-19 disease can also be treated with this drug. The potential treatment of COVID-19 can include hydroxychloroquine, combined with a can antibiotic azithromycin. In countries like India, it can be put over the counter and it is very cheap. However, its procurement is narrowly limited because recently discovered COVID-19 is being considered for therapy.

Key Players

Participants include major global players such Novartis, Actavis (TEVA ), Apotex Corporation, Sanofi, Hikma Pharmaceuticals, Mylan, Covis Pharmaceutical, Aphena Pharma, Concordia Healthcare, Cardinal Health, Cinkate Corporation, Zydus Cadila, Others.

The firms concentrate primarily on technological growth, acquisition and merger as well as global development to achieve a large market share. Given that the prescription substance is viewed as a possible treatment for COVID-19, the production of the hydrochloroquine medication has risen in significant numbers.

2020, Intas Pharmaceuticals Ltd announced a collaboration project on the prevention of COVID-19 with hydroxychloroquine approved by the World Health Organisation and aims to provide the project with the two million hydroxychloroquin tablets.

Market Segmentation

Hydroxychloroquine Market By Type

    --  200mg
    --  100mg
    --  Other

Hydroxychloroquine Market By Sales Channel

    --  COVID-19
    --  Rheumatoid Arthritis
    --  Lupus Erythematosus
    --  Others

Hydroxychloroquine Market By Geography

North America

    --  U.S.
    --  Canada


    --  UK
    --  Germany
    --  France
    --  Spain
    --  Rest of Europe


    --  China
    --  Japan
    --  India
    --  Australia
    --  South Korea
    --  Rest of Asia-Pacific

Latin America

    --  Mexico
    --  Brazil
    --  Rest of Latin America

Middle East & Africa

    --  GCC
    --  South Africa
    --  Rest of MEA

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1858

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1858

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 OR +1 408 900 9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:

Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: sales@acumenresearchandconsulting.com
Website: https://www.acumenresearchandconsulting.com

View original content:http://www.prnewswire.com/news-releases/hydroxychloroquine-market-size-worth-around-us-6-bn-by-2027-301058526.html

SOURCE Acumen Research and Consulting